CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($0.67), $1.07 better than the analyst estimate of ($1.74). Revenue for the quarter came in at $100 million versus the consensus estimate of $25.85 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.